➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Boehringer Ingelheim
Colorcon
Dow
Baxter

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,539,258

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,539,258
Title:Quinazoline derivatives for the treatment of cancer diseases
Abstract: The present invention relates to the use of quinazolines of formula (I), ##STR00001## wherein the groups R.sup.a to R.sup.d have the meanings given in the claims and specification, in cancer therapy.
Inventor(s): Solca; Flavio (Vienna, AT), Amelsberg; Andree (Southbury, CT), van Meel; Jacobus C. A. (Moedling, AT), Baum; Anke (Moedling, AT), Stehle; Gerd (Ehingen, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:14/739,299
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,539,258
Patent Claims: 1. A method for treating metastatic non-small cell lung cancer (NSCLC) of squamous histology in a second line patient having failed at least one prior chemotherapy regimen, the method comprising administering to said patient a therapeutically effective amount of the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, or a physiologically acceptable salt thereof.

2. The method of claim 1, wherein the 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, or a physiologically acceptable salt thereof, is used in monotherapy or in combination with another anti-tumour therapeutic agent.

3. The method of claim 2, wherein the other anti-tumour therapeutic agent is selected from the group consisting topoisomerase inhibitors, mitosis inhibitors, compounds which interact with nucleic acids, hormone antagonists, inhibitors of metabolic processes, cytokines, and antibodies.

4. The method of claim 2, wherein the other anti-tumour therapeutic agent is cis-platinum.

5. The method of claim 2, wherein the compound is 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Colorcon
Boehringer Ingelheim
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.